Independent Data Monitoring Committee finds clear efficacy for REGEN-COV ™ (casirivimab with imdevimab) in Phase 3 COVID-19 outpatient outcomes trial

Dear Investor, Please find attached a press release from our partner Regeneron:
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news